Medicines for Malaria Venture and
partners research and deliver new
effective and affordable antimalarials
to give populations at risk of malaria
a better chance of a healthy and
prosperous future. The ultimate goal
is for these medicines to contribute to
The lives of over 6 million people have been
saved from malaria between 2001 and 2015.This
impressive progress was made possible thanks
to the scale-up of control measures like bed nets,
insecticides, diagnostics and medicines. As a
result Millennium Development Goal 6.C, to halt
and begin to reverse the incidence of malaria by
2015, was achieved.
Yet, malaria remains a major cause and
consequence of poverty – disproportionally
affecting women and children. Eliminating and
ultimately eradicating the disease would vastly
improve the lives of many vulnerable families in
the developing world, helping to lift them out
Medicines for Malaria Venture (MMV) is committed to accelerating progress against malaria, so that no one is left without effective treatment. Since its foundation in 1999, MMV and its public and private partners have focused on developing medicines to cure, treat and prevent malaria. Our original objective was to deliver one new effective antimalarial before the end of 2010. To date, we have launched six new medicines that have already saved countless lives.
Striving to bring prosperity and health to all, the global community has put in place Sustainable Development Goals (SDG).
MMV is playing its part in this major effort by developing next-generation medicines. Our antimalarial portfolio of 65 projects is the largest ever assembled. There are nine new drugs in clinical development targeting unmet medical needs, including medicines for children, pregnant women, people suffering from relapsing or drug resistant malaria.
These are the antimalarials that will support the global call for health lives and wellbeing for all - young and old.
Coartem Dispersible (artemetherlumefantrine), a childfriendly formulation developed with Novartis;
Guilin’s artesunate injection, Artesun, for the treatment of severe malaria;
Eurartesim (dihydroartemisininpiperaquine) with Sigma-Tau;
Pyramax, (pyronaridineartesunate) with Shin Poong;
Pyramax Granules, a child-friendly formulation of Pyramax Guilin’s sulphadoxinepyrimethamine + artesunate amodiaquine (SP+AQ) for seasonal malaria chemoprevention, WHO prequalified with MMV’s support.